UK — The MHRA regulates all medical devices and licenses treatment drugs in the UK. Lawrence Tallon is the chief of the MHRA. The report was compiled by an independent commission and involved input from more than 12,000 people including patients and clinicians.

"The medical devices regulatory framework predominantly dates from a period where we were thinking about things like hip replacements and knee replacements, or smaller things like stethoscopes and plasters," Tallon said. "Unlike most of the medical products we're used to regulating, these products continue to change after the point of authorization."

"As new data gets fed in, they learn, they adapt, they drift," he added. The recommendations include continuously monitoring AI products and removing them from regulatory approval if they malfunction or become less effective over time. The recommendations include building a system for providers to report how tools are performing in their clinics, including when they malfunction or potentially inhibit patient care.

The recommendations include giving patients the right to know whether AI is involved in their care and easy access to information about the products involved. "What I would expect is that patients will increasingly see AI as part of the way that normal NHS healthcare is delivered," Tallon said. "That should happen in a way that they can maintain their trust and their confidence in what's happening."

A study from the University of Edinburgh found patients could be less likely to share personal information such as substance abuse history if they knew the conversation was being processed by AI. Professor Henrietta Hughes is a GP who was part of the report commission. She said some patients express reluctance, stating they do not want to talk to a robot, and that such concerns must be respected.

The recommendations include an AI "L plate" system to allow new AI models to be trialled by healthcare professionals under close supervision. The recommendations include allowing for the staged authorization of new AI models. The recommendations include the power to penalise developers of an AI product if it fails to meet required standards. The recommendations include building a system for providers to report how tools are performing in their clinics, including when they malfunction or potentially inhibit patient care.

Professor Alastair Denniston is an ophthalmologist who worked on the report. He described the development as "an exceptional opportunity" that is "likely to rank alongside step-changes such as antibiotics and MRI." AI note-takers known as scribes, which are powered by LLMs, are reportedly used by 40% of UK-based GPs to record consultations and generate reports.

Why It Matters

The recommendations address a regulatory gap created by adaptive technology that evolves after initial approval. Current frameworks were designed for static medical devices, creating a mismatch with AI systems that learn and change through use. The inclusion of patient disclosure rights and continuous monitoring aims to align regulatory oversight with the operational reality of these tools.

The involvement of more than 12,000 patients and clinicians indicates a broad consultation process behind the proposed changes. The potential for penalties and the introduction of trial systems like the "L plate" model represent a shift toward active management of AI performance in clinical settings. These measures seek to balance innovation with safety requirements in the NHS.

What's New

The U.K. commission unveiled its recommendations for regulating artificial intelligence in medicine on Thursday.

How Sources Differ

Sources differ on the specific details regarding the healthcare products regulatory agency. The Medicines and Healthcare Products Regulatory Agency report on AI regulation states that the Medicines and Healthcare Products Regulatory Agency (MHRA) published 44 recommendations to update policies for AI products used in the NHS and other healthcare settings. Gov.uk states that Medicines and Healthcare products Regulatory Agency is a Medicine regulation agency in the UK.